Fluoxetine (Sarafem) for premenstrual dysphoric disorder.
D000328:Adult; D002986:Clinical Trials as Topic; D003511:Cyclohexanols / Q000008:administration & dosage / Q000627:therapeutic use; D003866:Depressive Disorder / Q000188:drug therapy; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D005473:Fluoxetine / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D009325:Nausea / Q000139:chemically induced; D011293:Premenstrual Syndrome / Q000188:drug therapy*; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D020280:Sertraline / Q000008:administration & dosage / Q000627:therapeutic use; D000069470:Venlafaxine Hydrochloride; D015430:Weight Gain / Q000187:drug effects
D003511:Cyclohexanols; D005473:Fluoxetine; D017367:Selective Serotonin Reuptake Inhibitors; D020280:Sertraline; D000069470:Venlafaxine Hydrochloride